Novartis AG to Acquire Avidity Biosciences in $12B Deal (with Precision Cardiology SpinCo)

ATS Corporation Acquires Avidity Science

September 22, 2023

Medical Devices

ATS Corporation has entered into a definitive agreement to acquire Avidity Science, a designer and manufacturer of automated water purification and delivery systems for biomedical and life science applications, for US$195 million. The acquisition strengthens ATS's life sciences capabilities and is expected to close in Q4 2023 subject to customary regulatory filings.

Avidity Science Acquires Lab Products, Bio Medic Data Systems, Hydropac and Harford Systems

October 26, 2020

Medical Devices

Avidity Science, a ShoreView portfolio company, has acquired Lab Products, Inc. and its divisions — Bio Medic Data Systems, Hydropac and Harford Systems — expanding its portfolio of water purification and delivery products, control and monitoring solutions, and vivarium equipment for biomedical research. The transaction is the fifth add-on completed under ShoreView's ownership and is intended to broaden Avidity's product capabilities and geographic presence in the life-science research market.

Agilent Technologies Acquires Avida Biomed

January 4, 2023

Biotechnology

Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

GHO Capital and Ampersand Acquire Avid Bioservices for $1.1 Billion

November 7, 2024

Biotechnology

GHO Capital Partners and Ampersand Capital Partners have completed the acquisition of Avid Bioservices, a dedicated biologics CDMO, in an all-cash transaction valued at approximately $1.1 billion. The transaction takes Avid private (shareholders received $12.50 per share) and positions the company for capability expansion, geographic reach and accelerated growth under the new PE ownership.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.